secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001683168-24-008118
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q3 net loss $1.5M, cash $5.4M; PH-762 shows complete response in one patient
--------------------------------------------------------------------------------

- Net loss narrowed to $1.5M for Q3 2024 vs $2.8M in Q3 2023; R&D expenses fell 64% to $0.6M.
- Cash at Sept 30, 2024 was $5.4M, down from $8.5M at Dec 31, 2023.
- Phase 1b of PH-762: second cohort enrolled; one complete response (100% tumor clearance) and one partial response (90%) in cutaneous squamous cell carcinoma.
- Warrant inducement exercise in July 2024 raised net proceeds of ~$2.6M.
- Third cohort screening opens Dec 10, 2024; sixth clinical site added in San Diego.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824008118/0001683168-24-008118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824008118/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-008118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer